RT Journal Article
SR Electronic
T1 A privacy-preserving Bayesian network model for personalised COVID19 risk assessment and contact tracing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20154286
DO 10.1101/2020.07.15.20154286
A1 Norman E Fenton
A1 Scott McLachlan
A1 Peter Lucas
A1 Kudakwashe Dube
A1 Graham A Hitman
A1 Magda Osman
A1 Evangelia Kyrimi
A1 Martin Neil
YR 2020
UL http://medrxiv.org/content/early/2020/07/19/2020.07.15.20154286.abstract
AB Concerns about the practicality and effectiveness of using Contact Tracing Apps (CTA) to reduce the spread of COVID19 have been well documented and, in the UK, led to the abandonment of the NHS CTA shortly after its release in May 2020. One of the key non-technical obstacles to widespread adoption of CTA has been concerns about privacy. We present a causal probabilistic model (a Bayesian network) that provides the basis for a practical CTA solution that does not compromise privacy. Users of the model can provide as much or little personal information as they wish about relevant risk factors, symptoms, and recent social interactions. The model then provides them feedback about the likelihood of the presence of asymptotic, mild or severe COVID19 (past, present and projected). When the model is embedded in a smartphone app, it can be used to detect new outbreaks in a monitored population and identify outbreak locations as early as possible. For this purpose, the only data needed to be centrally collected is the probability the user has COVID19 and the GPS location.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge support from the EPSRC under project EP/P009964/1: PAMBAYESIAN: Patient Managed decision-support using Bayesian Networks and The Alan Turing Institute under the EPSRC grant EP/N510129/1. We also acknowledge the support of Agena.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLinks are provided in the article to data and model http://www.eecs.qmul.ac.uk/~norman/Models/covid19_for_contact_tracing_paper.cmpx